p53 and MDM2 expression in odontogenic cysts and tumours

Oral Diseases

Volumn 5, Issue 3, 1999, Pages 218-222

  Carvalhais, Júnia Noronha ^a   De Aguiar, M C F ^a   De Araujo V C ^b   De Araujo N S ^b   Gomez, R S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunohistochemistry; MDM2; Odontogenic cysts; Odontogenic tumours; P53

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AMELOBLASTOMA; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; ODONTOGENIC CYST; ODONTOGENIC TUMOR; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0032855995     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.1999.tb00304.x     Document Type: Article

References (35)

1. Barak Y, Juven T, Haffner R et al (1993). MDM2 expression is induced by wild-type p53 activity. EMBO J 12: 461.
2. Chang F, Syrjänen S, Tervahauta A et al (1993). Tumorigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653-661.
3. Chen CY, Oliner JD, Zhan Q et al (1994). Interactions between p53 and MDM2 in mammalian cell cycle check point pathway. Proc Natl Acad Sci USA 91: 2684.
4. Cordon-Cardo C, Latres E, Drobnjak M et al (1994). Molecular abnormalities of mdm2 and p53 gene in adult soft tissue sarcomas. Cancer Res 54: 794-799.
5. Courtney RM, Kerr DA (1975). The odontogenic adenomatoid tumour. A comprehensive study of twenty new cases. Oral Surg Oral Med Oral Pathol 39: 424-435.
6. Dominguez FV, Keszler A (1988). Comparation study of keratocysts associated and non-associated with nevoid basal cell carcinoma syndrome. J Oral Pathol 17: 39-42.
7. Farmer G, Bargonetti J, Zhu H et al (1992). Wild-type p53 activates transcription in vitro. Nature 358: 83-86.
8. Finlay CA (1993). The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301.
9. Florenes VA, Maeladsmo GM, Forus A et al (1994). MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86: 1297.
10. Forus A, Florenes VA, Maelandsmo GM et al (1993). Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Diff 4: 1065.
11. Greenblatt MS, Bennett WP, Hollstein M et al (1994). Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
12. Günther T, Schneider-Stock R, Rys J et al (1997). p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J Cancer Res Clin Oncol 123: 388-394.
13. Higashiyama M, Doi O, Kodama K et al (1997). MDM2 gene amplification and expression in non-small cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75: 1302-1308.
14. Landers JE, Cassel SL, George DL (1997). Translational enhancement of mdm2 oncogene expression in human tumour cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568.
15. Lane DP (1992). p53, guardian of the genome. Nature 358: 15-16.
16. Lane DP, Crawford LV (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
17. Leach FS, Tokino T, Meltzer P et al (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234.
18. Li TJ, Browne RM, Prime SS et al (1996). p53 expression in odontogenic keratocys epithelium. J Oral Pathol Med 25: 245-255.
19. Lombardi T, Odell EW, Morgan PR (1995). p53 immunohistochemistry of odontogenic keratocysts in relation to recurrence, basal-cell budding and basal-cell naevus syndrome. Arch Oral Biol 40: 1081-1084.
20. Martin K, Trouche D, Hagemeier C et al (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691.
21. Matsumura T, Yoshihama Y, Kimura T et al (1996). p53 and MDM2 expression in oral squamous cell carcinoma. Oncology 53: 308-312.
22. Moch H, Sauter G, Gasser TC et al (1997). p53 protein expression but not mdm2 protein expression is associated with rapid tumour cell proliferation and prognosis in renal cell carcinoma. Urol Res 1: 525-530.
23. Momand J, Zambetti GP, Olson DC et al (1992). The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
24. Ogden GR, Chisholm DM, Kiddie RA et al (1992). p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. J Clin Pathol 45: 1007-1010.
25. Oliner JD, Kinzler KW, Meltzer PS et al (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
26. Pilotti S, Della Torre G, Lavarino C et al (1997). Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenic mechanisms. J Pathol 181: 14-24.
27. Price BD, Park SJ (1994). DNA damage increases the levels of MDM2 messanger RNA in wtp53 human cells. Cancer Res 54: 896-899.
28. Reifenberger G, Liu L, Ichimura K et al (1993). Amplification and overexpression of MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739.
29. Skomedal H, Kristensen GB, Abeler VM et al (1997). TP53 protein accumulation and gene mutation in relation to overexpression of mdm2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 181: 158-165.
30. Slootweg PJ (1995). p53 protein and Ki67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 24: 393-397.
31. Stefanaki K, Rontogiani D, Kouvidou CH et al (1997). Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathology 30: 549-555.
32. WAF1/CIP1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, mdm2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 181: 51-61.
33. Werness BA, Levine AJ, Howley PM (1990). Association of human papillomavirus types 16 and 18 E6 protein with p53. Science 248: 76-79.
34. Wu X, Bayle JH, Olson D et al (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126.
35. Wynford-Thomas D (1992). p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 166: 329-330.